Literature DB >> 22435550

Regulation of NF-κB by deubiquitinases.

Edward W Harhaj1, Vishva M Dixit.   

Abstract

The nuclear factor-κB (NF-κB) pathway is a critical regulator of innate and adaptive immunity. Noncanonical K63-linked polyubiquitination plays a key regulatory role in NF-κB signaling pathways by functioning as a scaffold to recruit kinase complexes containing ubiquitin-binding domains. Ubiquitination is balanced by deubiquitinases that cleave polyubiquitin chains and oppose the function of E3 ubiquitin ligases. Deubiquitinases therefore play an important role in the termination of NF-κB signaling and the resolution of inflammation. In this review, we focus on NF-κB regulation by deubiquitinases with an emphasis on A20 and CYLD. Deubiquitinases and the ubiquitin/proteasome components that regulate NF-κB may serve as novel therapeutic targets for inflammatory diseases and cancer.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22435550      PMCID: PMC3540820          DOI: 10.1111/j.1600-065X.2012.01100.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  209 in total

1.  The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice.

Authors:  W L Perry; C M Hustad; D A Swing; T N O'Sullivan; N A Jenkins; N G Copeland
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

2.  GLI1-dependent transcriptional repression of CYLD in basal cell carcinoma.

Authors:  S Kuphal; G Shaw-Hallgren; M Eberl; S Karrer; F Aberger; A K Bosserhoff; R Massoumi
Journal:  Oncogene       Date:  2011-05-16       Impact factor: 9.867

3.  A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies.

Authors:  Nadine Hövelmeyer; Sonja Reissig; Nguyen Thi Xuan; Petra Adams-Quack; Dominika Lukas; Alexei Nikolaev; Dirk Schlüter; Ari Waisman
Journal:  Eur J Immunol       Date:  2011-02-10       Impact factor: 5.532

4.  Reduced expression of CYLD in human colon and hepatocellular carcinomas.

Authors:  Claus Hellerbrand; Elisabeth Bumes; Frauke Bataille; Wolfgang Dietmaier; Ramin Massoumi; Anja K Bosserhoff
Journal:  Carcinogenesis       Date:  2006-06-13       Impact factor: 4.944

Review 5.  Expanding role of ubiquitination in NF-κB signaling.

Authors:  Siqi Liu; Zhijian J Chen
Journal:  Cell Res       Date:  2010-12-07       Impact factor: 25.617

6.  Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation.

Authors:  William Reiley; Minying Zhang; Xuefeng Wu; Erica Granger; Shao-Cong Sun
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

7.  TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.

Authors:  Keiichiro Honma; Shinobu Tsuzuki; Masao Nakagawa; Hiroyuki Tagawa; Shigeo Nakamura; Yasuo Morishima; Masao Seto
Journal:  Blood       Date:  2009-07-16       Impact factor: 22.113

8.  Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation.

Authors:  Jessica E Hutti; Rhine R Shen; Derek W Abbott; Alicia Y Zhou; Kam M Sprott; John M Asara; William C Hahn; Lewis C Cantley
Journal:  Mol Cell       Date:  2009-05-14       Impact factor: 17.970

9.  Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection.

Authors:  Stephen E Girardin; Ivo G Boneca; Jérôme Viala; Mathias Chamaillard; Agnès Labigne; Gilles Thomas; Dana J Philpott; Philippe J Sansonetti
Journal:  J Biol Chem       Date:  2003-01-13       Impact factor: 5.157

10.  AIP4/Itch regulates Notch receptor degradation in the absence of ligand.

Authors:  Patricia Chastagner; Alain Israël; Christel Brou
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

View more
  137 in total

Review 1.  Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways.

Authors:  Samuel E Vaughn; Leah C Kottyan; Melissa E Munroe; John B Harley
Journal:  J Leukoc Biol       Date:  2012-06-29       Impact factor: 4.962

2.  PLK4 deubiquitination by Spata2-CYLD suppresses NEK7-mediated NLRP3 inflammasome activation at the centrosome.

Authors:  Xiao-Dong Yang; Wenguo Li; Shuangyan Zhang; Dandan Wu; Xiaoli Jiang; Rong Tan; Xiaoyin Niu; Qijun Wang; Xuefeng Wu; Zhiduo Liu; Lin-Feng Chen; Jun Qin; Bing Su
Journal:  EMBO J       Date:  2019-11-25       Impact factor: 11.598

Review 3.  TNF biology, pathogenic mechanisms and emerging therapeutic strategies.

Authors:  George D Kalliolias; Lionel B Ivashkiv
Journal:  Nat Rev Rheumatol       Date:  2015-12-10       Impact factor: 20.543

4.  TNFAIP3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy.

Authors:  Yu Matsuzawa; Shigeru Oshima; Masahiro Takahara; Chiaki Maeyashiki; Yasuhiro Nemoto; Masanori Kobayashi; Yoichi Nibe; Kengo Nozaki; Takashi Nagaishi; Ryuichi Okamoto; Kiichiro Tsuchiya; Tetsuya Nakamura; Averil Ma; Mamoru Watanabe
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

5.  Tumor suppressor cylindromatosis (CYLD) controls HIV transcription in an NF-κB-dependent manner.

Authors:  Lara Manganaro; Lars Pache; Tobias Herrmann; John Marlett; Young Hwang; Jeffrey Murry; Lisa Miorin; Adrian T Ting; Renate König; Adolfo García-Sastre; Frederic D Bushman; Sumit K Chanda; John A T Young; Ana Fernandez-Sesma; Viviana Simon
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

Review 6.  The 'ubiquitous' reality of vector immunology.

Authors:  Maiara S Severo; Olivia S Sakhon; Anthony Choy; Kimberly D Stephens; Joao H F Pedra
Journal:  Cell Microbiol       Date:  2013-03-14       Impact factor: 3.715

7.  All roads lead to ubiquitin.

Authors:  Mads Gyrd-Hansen
Journal:  Cell Death Differ       Date:  2017-07       Impact factor: 15.828

Review 8.  Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases.

Authors:  Junying Yuan; Palak Amin; Dimitry Ofengeim
Journal:  Nat Rev Neurosci       Date:  2019-01       Impact factor: 34.870

Review 9.  When ubiquitin meets NF-κB: a trove for anti-cancer drug development.

Authors:  Zhao-Hui Wu; Yuling Shi
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 10.  Deubiquitinating enzymes as promising drug targets for infectious diseases.

Authors:  Bindu Nanduri; Akamol E Suvarnapunya; Malabi Venkatesan; Mariola J Edelmann
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.